Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bemnifosbuvir in High-Risk Outpatients with COVID-19
2022-003268-25Phase 3Active
- Sponsor
- Atea Pharmaceuticals
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Bemnifosbuvir arm with Placebo arm (2 arms). Primary endpoint: Primary efficacy endpoint. Started Dec 2022; status: active.
02
Drugs
bemnifosbuvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2022-003268-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-003268-25.